查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933376

全球孕產婦健康治療市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Maternal Health Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

孕產婦健康治療市場成長因素

受政府對孕產婦保健日益重視、女性健康項目投資增加以及妊娠併發症增加等因素的推動，全球孕產婦健康治療市場在2025年呈現穩定成長態勢。報告顯示，全球孕產婦健康治療市場預計在2025年達到46億美元，從2026年的49.1億美元成長至2034年的88.4億美元，預測期內複合年增長率（CAGR）為7.63%。 北美地區在2025年將以42.32%的市場佔有率領跑，這主要得益於其強大的醫療保健基礎設施、不斷增長的機構分娩率以及先進治療手段的普及。

孕產婦健康治療藥物包括用於治療妊娠併發症的藥物，例如子癇前症、妊娠期糖尿病、產後出血和產後憂鬱症，這些藥物適用於孕前、懷孕和產後。生活方式相關疾病的增加、妊娠延遲以及分娩併發症的增多，都推動了對專業治療方案的需求。此外，多家製藥公司正在加強研發管線，以滿足孕產婦保健領域尚未滿足的需求。

市場動態

市場驅動因素

全球出生率的持續成長仍然是孕產婦健康治療藥物市場的主要驅動因素。不斷增長的孕產婦人口直接擴大了妊娠相關併發症的風險族群，從而推動了對子宮收縮抑制劑、降血壓藥、胰島素、抗生素和抗憂鬱藥物的需求。 機構分娩率的提高和醫療保健服務可近性的改善進一步支持了市場成長。

根據聯合國兒童基金會（2023 年）的數據，全球將有約 1,321.1 億新生兒出生，這凸顯了對產科護理服務和藥物日益增長的需求。

市場限制因子

一個主要的限制因素是妊娠專用藥物的短缺。許多用於治療孕產婦併發症的藥物屬於超適應症用藥，是為一般人開發的。這種依賴性引發了人們對孕產婦安全、劑量優化和長期療效的擔憂。

2023 年 12 月，世界衛生組織 (WHO) 報告稱，每年至少有 4,000 萬名婦女遭受分娩帶來的長期健康問題，這凸顯了儘管疾病負擔沉重，但治療方面仍然存在缺口。

市場機會

產後護理領域的創新提供了巨大的成長機會。 產後疾病，如產後出血、憂鬱症和感染，是促使孕產婦發病率和死亡率的重要因素，但這些疾病仍未得到充分治療。

2023年12月，渤健公司與Sage Therapeutics公司合作，在美國推出了用於治療成人產後憂鬱症的藥物Zurzuvae，這顯示人們對產後藥物的興趣日益濃厚。

市場挑戰

低收入國家孕產婦保健藥物的可近性有限，這是一項重大挑戰。薄弱的供應鏈、供應不穩定以及醫療基礎設施的匱乏阻礙了藥物的有效分發。

根據聯合國兒童基金會（2024年）的數據，南蘇丹、查德和索馬利亞等國仍面臨醫療設施嚴重短缺的問題，儘管需求不斷增長，但這些國家獲得基本孕產婦藥物的機會仍然有限。

孕產婦健康治療市場趨勢

影響市場發展的關鍵趨勢之一是政府對孕產婦保健的支持力度不斷增加。世界各國政府正透過國家計畫、資金支持計畫和政策改革，將孕產婦安全放在首位。

2024年2月，美國衛生與公眾服務部 (HHS) 啟動了由部長領導的產後孕產婦健康合作項目，旨在解決產後死亡率問題，這標誌著政策層面的投入力度加大。

市場區隔分析

依藥物類型劃分，預計到2026年，不孕症藥物將佔市場主導地位，市佔率達33.39%。同時，由於產後出血大量使用子宮收縮劑，荷爾蒙療法也佔了相當大的市場。 依適應症劃分，預計妊娠期糖尿病將在 2026 年佔 27.09% 的市場佔有率，引領市場。產後出血在 2025 年佔 15.7% 的市佔率。依階段劃分，預計孕前階段將在 2026 年佔 42.25% 的市場佔有率，而產後階段預計將出現強勁增長。依給藥途徑劃分，口服療法預計在2026年將維持55.10%的市佔率。依分銷管道劃分，醫院藥房將在2025年佔主導地位，市場佔有率達到50.8%，這主要得益於其在管理高風險孕產婦疾病方面發揮的作用。

區域展望

北美市場領先，預計2025年將達到19.5億美元，2026年將達到20.8億美元，這主要受產後憂鬱症、子癇前症和妊娠期糖尿病病例增加的推動。歐洲市場預計在2025年將達到11.9億美元，這得益於公眾意識的提高和醫療保健投資的增加。亞太地區緊追在後，預計2025年將達到11.4億美元，其次是拉丁美洲和中東及非洲，分別為1.9億美元和6,000萬美元。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家的監管環境
  • 主要公司的產品線分析
  • 主要疾病和主要國家的流行病學
  • 關鍵產業趨勢：併購、業務合作、新產品發表等

第五章：全球孕產婦健康治療市場分析：洞察與預測 (2021-2034)

  • 市場分析、洞察與預測：依藥物類型劃分
    • 荷爾蒙療法
    • 促性腺激素釋放激素 (GnRH) 調節劑
    • 疼痛管理/症狀管理
    • 代謝療法
    • 不孕症藥物
    • 其他
  • 市場分析、洞察與預測：依適應症劃分
    • 子癇前症/妊娠高血壓
    • 妊娠糖尿病
    • 產後出血
    • 產後憂鬱症
    • 妊娠劇吐
    • FNAIT（束狀同種免疫性血小板減少症）
    • 產後子宮內膜炎
    • 其他
  • 市場分析、洞察與預測：依階段
    • 懷孕前
    • 懷孕前
    • 圍產期
    • 產後
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測：依銷售管道
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美孕產婦健康治療市場分析：洞察與預測 （2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲孕產婦健康治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區孕產婦健康治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 東南亞亞洲
    • 澳大利亞
    • 亞太其他地區

第九章：拉丁美洲孕產婦健康治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲孕產婦健康治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）成員國
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
  • Novartis AG
  • Johnson &Johnson
  • Shionogi &Co., Ltd.
  • Bayer AG(Germany)
  • Bristol-Myers Squibb Company
  • Biogen
  • Pfizer Inc.
  • Merck &Co., Inc.,
Product Code: FBI114309

Growth Factors of maternal health therapeutics Market

The global maternal health therapeutics market demonstrated steady growth in 2025, supported by rising government focus on maternal healthcare, increasing investments in women's health programs, and a growing burden of pregnancy-related complications. According to the report, the global maternal health therapeutics market size was valued at USD 4.6 billion in 2025 and is projected to grow from USD 4.91 billion in 2026 to USD 8.84 billion by 2034, registering a CAGR of 7.63% during the forecast period. North America dominated the market with a 42.32% share in 2025, owing to strong healthcare infrastructure, higher institutional births, and greater access to advanced therapeutics.

Maternal health therapeutics include drugs used across preconception, pregnancy, labor & delivery, and postpartum stages to manage complications such as preeclampsia, gestational diabetes, postpartum hemorrhage, and postpartum depression. The rising prevalence of lifestyle-related disorders, delayed pregnancies, and increasing birth complications is driving demand for specialized therapeutic solutions. Additionally, several pharmaceutical companies are strengthening their pipelines to address unmet needs in maternal care.

Market Dynamics

Market Drivers

The rising number of births globally remains a major driver of the maternal health therapeutics market. An increasing maternal population directly expands the risk pool for pregnancy-related complications, driving demand for uterotonics, antihypertensives, insulin, antibiotics, and antidepressants. Growing institutional deliveries and improved access to healthcare services are further supporting market growth.

According to UNICEF (2023), approximately 132.11 billion births were reported globally, highlighting the expanding demand for maternal healthcare services and therapeutics.

Market Restraints

A key restraint is the lack of pregnancy-specific therapeutics. Many drugs used for maternal complications are off-label treatments initially developed for the general population. This reliance raises concerns related to safety, dosage optimization, and long-term outcomes for pregnant and postpartum women.

In December 2023, the World Health Organization (WHO) reported that at least 40.0 million women annually experience long-term health problems caused by childbirth, underscoring the existing treatment gap despite a high disease burden.

Market Opportunities

Innovation in postpartum care offers a major growth opportunity. Postpartum conditions such as hemorrhage, depression, and infections contribute significantly to maternal morbidity and mortality but remain underserved.

In December 2023, Biogen Inc., in collaboration with Sage Therapeutics, launched ZURZUVAE for the treatment of postpartum depression in adults in the U.S., highlighting the growing focus on postpartum therapeutics.

Market Challenges

Limited access to maternal health therapeutics in low-income countries poses a critical challenge. Weak supply chains, inconsistent availability, and poor healthcare infrastructure restrict effective drug distribution.

According to UNICEF (2024), countries such as South Sudan, Chad, and Somalia continue to face inadequate healthcare facilities, limiting access to essential maternal medicines despite growing demand.

Maternal Health Therapeutics Market Trends

An important trend shaping the market is increasing government support for maternal healthcare. Governments are prioritizing maternal safety through national programs, funding initiatives, and policy reforms.

In February 2024, the U.S. Department of Health and Human Services (HHS) launched the Secretary's Postpartum Maternal Health Collaborative to address postpartum mortality, reflecting rising policy-level commitment.

Segmentation Analysis

By drug type, fertility drugs are projected to dominate with a 33.39% share in 2026, while hormonal therapies hold a significant share due to high utilization of uterotonics for postpartum hemorrhage. By application, gestational diabetes is projected to lead with a 27.09% share in 2026, while postpartum hemorrhage accounted for 15.7% share in 2025. By phase, preconception is expected to account for 42.25% share in 2026, while the postpartum segment is anticipated to witness strong growth. By route of administration, oral therapies are projected to hold 55.10% share in 2026. By distribution channel, hospital pharmacies dominated with a 50.8% share in 2025, supported by their role in managing high-risk maternal conditions.

Regional Outlook

North America led the market with USD 1.95 billion in 2025 and USD 2.08 billion in 2026, driven by rising cases of postpartum depression, preeclampsia, and gestational diabetes. Europe reached USD 1.19 billion in 2025, supported by increasing awareness and healthcare investments. Asia Pacific followed with USD 1.14 billion in 2025, while Latin America and the Middle East & Africa recorded USD 0.19 billion and USD 0.06 billion, respectively.

Competitive Landscape

The market is semi-consolidated, with key players such as Johnson & Johnson, Novartis AG, Pfizer Inc., Biogen, and Merck & Co., Inc. focusing on collaborations, R&D investments, and strategic initiatives to expand their maternal health portfolios.

Conclusion

The global maternal health therapeutics market was valued at USD 4.6 billion in 2025 and is expected to grow from USD 4.91 billion in 2026 to USD 8.84 billion by 2034, driven by rising birth rates, increasing maternal complications, strong government support, and expanding pharmaceutical pipelines. North America maintained market leadership, while Europe and Asia Pacific demonstrated significant growth potential. Despite challenges such as limited access in low-income countries and reliance on off-label therapies, continued innovation in postpartum care, supportive government initiatives, and growing awareness of maternal health are expected to sustain market expansion through 2034.

Segmentation By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Region

By Drug Type * Hormonal Therapies

  • GnRH Modulators
  • Pain & Symptom Management
  • Metabolic Drugs
  • Fertility Drugs
  • Others

By Application * Preeclampsia & Gestational Hypertension

  • Gestational Diabetes
  • Postpartum Hemorrhage
  • Postpartum Depression
  • Hyperemesis Gravidarum
  • Alloimmune Thrombocytopenia (FNAIT)
  • Postpartum Endometritis
  • Others

By Phase * Preconception

  • Prenatal
  • Labor & delivery
  • Postnatal/ Postpartum

By Route of Administration * Oral

  • Parenteral

By Distribution Channel * Hospital Pharmacies

  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography * North America (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Epidemiology- Key Diseases, By Key Countries/ Regions
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Type
    • 5.1.1. Hormonal Therapies
    • 5.1.2. GnRH Modulators
    • 5.1.3. Pain & Symptom Management
    • 5.1.4. Metabolic Drugs
    • 5.1.5. Fertility Drugs
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Preeclampsia & Gestational Hypertension
    • 5.2.2. Gestational Diabetes
    • 5.2.3. Postpartum Hemorrhage
    • 5.2.4. Postpartum Depression
    • 5.2.5. Hyperemesis Gravidarum
    • 5.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 5.2.7. Postpartum Endometritis
    • 5.2.8. Others
  • 5.3. Market Analysis, Insights and Forecast - By Phase
    • 5.3.1. Preconception
    • 5.3.2. Prenatal
    • 5.3.3. Labor & Delivery
    • 5.3.4. Postnatal/ Postpartum
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Oral
    • 5.4.2. Parenteral
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Type
    • 6.1.1. Hormonal Therapies
    • 6.1.2. GnRH Modulators
    • 6.1.3. Pain & Symptom Management
    • 6.1.4. Metabolic Drugs
    • 6.1.5. Fertility Drugs
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Preeclampsia & Gestational Hypertension
    • 6.2.2. Gestational Diabetes
    • 6.2.3. Postpartum Hemorrhage
    • 6.2.4. Postpartum Depression
    • 6.2.5. Hyperemesis Gravidarum
    • 6.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 6.2.7. Postpartum Endometritis
    • 6.2.8. Others
  • 6.3. Market Analysis, Insights and Forecast - By Phase
    • 6.3.1. Preconception
    • 6.3.2. Prenatal
    • 6.3.3. Labor & delivery
    • 6.3.4. Postnatal/ Postpartum
  • 6.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.4.1. Oral
    • 6.4.2. Parenteral
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Type
    • 7.1.1. Hormonal Therapies
    • 7.1.2. GnRH Modulators
    • 7.1.3. Pain & Symptom Management
    • 7.1.4. Metabolic Drugs
    • 7.1.5. Fertility Drugs
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Preeclampsia & Gestational Hypertension
    • 7.2.2. Gestational Diabetes
    • 7.2.3. Postpartum Hemorrhage
    • 7.2.4. Postpartum Depression
    • 7.2.5. Hyperemesis Gravidarum
    • 7.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 7.2.7. Postpartum Endometritis
    • 7.2.8. Others
  • 7.3. Market Analysis, Insights and Forecast - By Phase
    • 7.3.1. Preconception
    • 7.3.2. Prenatal
    • 7.3.3. Labor & delivery
    • 7.3.4. Postnatal/ Postpartum
  • 7.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.4.1. Oral
    • 7.4.2. Parenteral
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Type
    • 8.1.1. Hormonal Therapies
    • 8.1.2. GnRH Modulators
    • 8.1.3. Pain & Symptom Management
    • 8.1.4. Metabolic Drugs
    • 8.1.5. Fertility Drugs
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Preeclampsia & Gestational Hypertension
    • 8.2.2. Gestational Diabetes
    • 8.2.3. Postpartum Hemorrhage
    • 8.2.4. Postpartum Depression
    • 8.2.5. Hyperemesis Gravidarum
    • 8.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 8.2.7. Postpartum Endometritis
    • 8.2.8. Others
  • 8.3. Market Analysis, Insights and Forecast - By Phase
    • 8.3.1. Preconception
    • 8.3.2. Prenatal
    • 8.3.3. Labor & delivery
    • 8.3.4. Postnatal/ Postpartum
  • 8.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.4.1. Oral
    • 8.4.2. Parenteral
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Southeast Asia
    • 8.6.5. Australia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Type
    • 9.1.1. Hormonal Therapies
    • 9.1.2. GnRH Modulators
    • 9.1.3. Pain & Symptom Management
    • 9.1.4. Metabolic Drugs
    • 9.1.5. Fertility Drugs
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Preeclampsia & Gestational Hypertension
    • 9.2.2. Gestational Diabetes
    • 9.2.3. Postpartum Hemorrhage
    • 9.2.4. Postpartum Depression
    • 9.2.5. Hyperemesis Gravidarum
    • 9.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 9.2.7. Postpartum Endometritis
    • 9.2.8. Others
  • 9.3. Market Analysis, Insights and Forecast - By Phase
    • 9.3.1. Preconception
    • 9.3.2. Prenatal
    • 9.3.3. Labor & delivery
    • 9.3.4. Postnatal/ Postpartum
  • 9.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.4.1. Oral
    • 9.4.2. Parenteral
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Type
    • 10.1.1. Hormonal Therapies
    • 10.1.2. GnRH Modulators
    • 10.1.3. Pain & Symptom Management
    • 10.1.4. Metabolic Drugs
    • 10.1.5. Fertility Drugs
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Preeclampsia & Gestational Hypertension
    • 10.2.2. Gestational Diabetes
    • 10.2.3. Postpartum Hemorrhage
    • 10.2.4. Postpartum Depression
    • 10.2.5. Hyperemesis Gravidarum
    • 10.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 10.2.7. Postpartum Endometritis
    • 10.2.8. Others
  • 10.3. Market Analysis, Insights and Forecast - By Phase
    • 10.3.1. Preconception
    • 10.3.2. Prenatal
    • 10.3.3. Labor & delivery
    • 10.3.4. Postnatal/ Postpartum
  • 10.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.4.1. Oral
    • 10.4.2. Parenteral
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Novartis AG
    • 11.2.2. Johnson & Johnson
    • 11.2.3. Shionogi & Co., Ltd.
    • 11.2.4. Bayer AG (Germany)
    • 11.2.5. Bristol-Myers Squibb Company
    • 11.2.6. Biogen
    • 11.2.7. Pfizer Inc.
    • 11.2.8. Merck & Co., Inc.,

List of Tables

  • Table 1: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 2: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 4: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 5: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 8: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 9: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 10: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 14: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 15: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase 2021-2034
  • Table 16: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 17: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 20: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 21: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 22: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 26: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 27: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 28: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 32: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 33: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 34: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 35: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Maternal Health Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025 & 2034
  • Figure 3: Global Maternal Health Therapeutics Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Maternal Health Therapeutics Market Value Share (%), by Phase 2025 & 2034
  • Figure 5: Global Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 6: Global Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Maternal Health Therapeutics Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 9: North America Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 10: North America Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 11: North America Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 12: North America Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 13: North America Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 14: North America Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 15: North America Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 16: North America Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Maternal Health Therapeutics Market Value (USD billion), by Country, 2025 & 2034
  • Figure 19: North America Maternal Health Therapeutics Market Value Share (%), by Country, 2025
  • Figure 20: Europe Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 21: Europe Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 22: Europe Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 23: Europe Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 24: Europe Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 25: Europe Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 26: Europe Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 27: Europe Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 28: Europe Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Maternal Health Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Maternal Health Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 33: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 34: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 35: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 36: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 37: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 38: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 39: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 40: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 44: Latin America Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 45: Latin America Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 46: Latin America Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 47: Latin America Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 48: Latin America Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 49: Latin America Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 50: Latin America Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 51: Latin America Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 52: Latin America Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Maternal Health Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Maternal Health Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 57: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 58: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 59: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 60: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 61: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 62: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 63: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 64: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 68: Global Maternal Health Therapeutics Market Share (%), by Company, 2025